Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.49
- Piotroski Score 2.00
- Grade Buy
- Symbol (IMMX)
- Company Immix Biopharma, Inc.
- Price $1.68
- Changes Percentage (-7.69%)
- Change -$0.14
- Day Low $1.65
- Day High $1.89
- Year High $7.75
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $7.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.93
- Trailing P/E Ratio -2.18
- Forward P/E Ratio -2.18
- P/E Growth -2.18
- Net Income $-15,426,048
Income Statement
Quarterly
Annual
Latest News of IMMX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History
Immix Biopharma, Inc. is a biopharmaceutical company focused on developing tissue-specific therapeutics for cancer and immune-related diseases. They are currently working on clinical trials for soft t...
By Yahoo! Finance | 3 months ago -
Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History - Yahoo Finance
Immix Biopharma is a US-based biopharmaceutical company developing tissue-specific therapeutics for cancer and immune diseases. They are conducting clinical trials for IMX-110 and NXC-201, with a coll...
By Yahoo! Finance | 3 months ago -
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Investors are attracted to unprofitable companies like Immix Biopharma due to potential success. Analyzing cash burn, it had a cash runway of 2.2 years in March 2024. Despite growing cash burn, the co...
By Yahoo! Finance | 4 months ago
